Clinical trials
catalyst calendar across sponsors →Studies where GLUE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 11 tracked-famous managers (MARSHALL WACE, LLP, AQR CAPITAL MANAGEMENT LLC, Duquesne Family Office LLC, Balyasny Asset Management L.P., D. E. Shaw & Co., Inc., +6 more) · FINRA short interest 10.6 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 14 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361Assess the efficacy of MRT-2359 combined with apalutamideOpen-label · Treatment | Phase 2 | Recruiting | Drug: Oral MRT-2359, Apalutamide | Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma) | 25 | Oct 2027 | ≤ 438 d | 2026-08-04 |
| A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRPNCT07119125To evaluate the safety and tolerability of single doses of MRT-8102 in healthy adult participantsRandomized · Quadruple-masked · Treatment | Phase 1 | Active, not recruiting | Drug: MRT-8102, Placebo | Healthy Volunteers, Elevated CRP | 100 | Jul 2026 | — | 2026-06-04 |
| Study of Oral MRT-2359 in Selected Cancer PatientsNCT05546268Phase 1 Evaluates safety and tolerability of MRT-2359 over a 28-day cycle by the occurrence and frequency of dose limiting toxicities (DLTs) for determination of the MTD and/or RP2DNon-randomized · Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359, Oral MRT-2359 | NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer | 174 | May 2026 | — | 2026-03-03 |
| First-in-human Study of MRT-6160 in Healthy SubjectsNCT06597799To evaluate the safety and tolerability of single ascending doses of MRT-6160 in healthy adult subjectsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: MRT-6160, Placebo | Healthy Volunteers | 108 | 2025-04-10actual | — | 2025-07-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19